Karyopharm Therapeutics Inc. (KPTI) News

Latest headlines that mention KPTI, newest first · each headline opens the original publisher

KPTI quote

Last price: $0.60
Day change: -6.98%
Next earnings: 2026-11-02

Quote & chart Expected move Insider trading IV rank history

KPTI headlines

latest coverage

Yahoo Finance 27d ago

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use

General T2AMGN KPTI

Yahoo Finance 1mo ago

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

General T2KPTI

Motley Fool 1mo ago

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Biotech pivots to hematology after endometrial cancer setback, faces debt deadline.

Earnings T3KPTI

Yahoo Finance 1mo ago

Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary

Earnings T2KPTI

Seeking Alpha 1mo ago

Karyopharm outlines potential myelofibrosis approval and launch as early as Q1 2027 while targeting up to ~$1B in U.S. peak revenue

Earnings T2KPTI

Seeking Alpha News 1mo ago

Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript

Earnings T2KPTI

Seeking Alpha News 1mo ago

Karyopharm Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

Earnings T2KPTI

Seeking Alpha 1mo ago

Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook

Earnings T2KPTI

Seeking Alpha 1mo ago

Karyopharm Therapeutics Q2 2026 Earnings Preview

Earnings T2KPTI

Seeking Alpha 2mo ago

Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer

General T2KPTI

Investing.com 2mo ago

Karyopharm endometrial cancer trial misses primary endpoint

General T3KPTI

Investing.com 2mo ago

Karyopharm plans myelofibrosis drug filing in August

General T3KPTI

Seeking Alpha News 2mo ago

Karyopharm: 'Hold' On Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck

General T2KPTI

Seeking Alpha News 2mo ago

Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead

General T2KPTI

Seeking Alpha 2mo ago

Karyopharm drops 21% following disclosure of executive cash retention plan

General T2KPTI

Seeking Alpha News 3mo ago

Karyopharm: Xpovio Revenue Stagnation And Toxicity Concerns Justify Sell

Earnings T2KPTI

Investing.com 4mo ago

Form 13G KARYOPHARM THERAPEUTICS INC For: 5 June

General T3KPTI

Seeking Alpha News 4mo ago

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis Transcript

General T2KPTI

Seeking Alpha News 4mo ago

Karyopharm Therapeutics Inc. (KPTI) Discusses Phase III SENTRY Trial Results of Selinexor Plus Ruxolitinib in Myelofibrosis - Slideshow

General T2KPTI

Investing.com 4mo ago

Karyopharm’s myelofibrosis trial selected for EHA presentation

General T3KPTI

Investing.com 4mo ago

Karyopharm reports phase 3 myelofibrosis trial results at ASCO

General T3KPTI

Investing.com 4mo ago

Karyopharm to host call on phase 3 myelofibrosis trial results

General T3KPTI

Investing.com 4mo ago

Earnings call transcript: Karyopharm Q1 2026 results disappoint, stock drops

Earnings T3KPTI

Seeking Alpha 4mo ago

Karyopharm outlines $130M-$150M 2026 revenue outlook as it prepares mid-2026 XPORT-EC-042 readout

Earnings T2KPTI

Seeking Alpha News 4mo ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2026 Earnings Call Transcript

Earnings T2KPTI

Motley Fool 4mo ago

Karyopharm (KPTI) Q1 2026 Earnings Transcript

Image source: The Motley Fool. Thursday, May 14, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

Earnings T3KPTI

Yahoo Finance 4mo ago

Karyopharm Therapeutics Q1 Earnings Call Highlights

Earnings T2KPTI

Seeking Alpha News 4mo ago

Karyopharm Therapeutics Inc. 2026 Q1 - Results - Earnings Call Presentation

Earnings T2KPTI

Seeking Alpha 4mo ago

Karyopharm Therapeutics GAAP EPS of -$1.24 beats by $0.25, revenue of $35.07M beats by $3.67M

Earnings T2KPTI

Seeking Alpha 4mo ago

Karyopharm Therapeutics Q1 2026 Earnings Preview

Earnings T2KPTI

Also mentioned with KPTI

30d

AMGN1

Headlines that tag both tickers

KPTI news alerts

Get an alert by email or push when a new headline mentions KPTI.

More news

News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.